Empesertib

Empesertib (BAY1161909) is an experimental drug which acts as a selective inhibitor of the enzyme monopolar spindle 1 kinase (MPS1). It is in clinical trials for the treatment of breast cancer.[1][2]

## References

1. ↑ "Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective". European Journal of Medicinal Chemistry 175: 247–268. August 2019. doi:10.1016/j.ejmech.2019.04.047. PMID 31121430.
2. ↑ "Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase". Journal of Medicinal Chemistry 63 (15): 8025–8042. August 2020. doi:10.1021/acs.jmedchem.9b02035. PMID 32338514.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Empesertib. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Empesertib&oldid=4032281"